These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2081205)

  • 41. High-performance liquid chromatographic assay of clavulanate in human plasma and urine by fluorimetric detection.
    Haginaka J; Yasuda H; Uno T; Nakagawa T
    J Chromatogr; 1986 Apr; 377():269-77. PubMed ID: 3711217
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oral bioavailability of ampicillin and amoxycillin alone and bound in fixed proportions to sulbactam and clavulanic acid.
    Desager JP; Costermans J; Van Nieuwenhuyze Y; Harvengt C
    J Int Med Res; 1989; 17(6):532-8. PubMed ID: 2628130
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of beta-lactamase inhibitors.
    Sutherland R
    J Reprod Med; 1990 Mar; 35(3 Suppl):307-12. PubMed ID: 2319512
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sulbactam and clavulanic acid: enzyme kinetics and synergy with ampicillin and mezlocillin.
    Cullmann W; Binder S; Stieglitz M
    Int J Antimicrob Agents; 1996 Apr; 6 Suppl():S1-7. PubMed ID: 18611714
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rapid and Simultaneous Quantitation of Amoxicillin and Clavulanic Acid in Human Plasma and Urine by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry and Its Application to a Pharmacokinetic Study.
    Fan Y; Wu X; Zhao M; Guo B; Cao G; Yu J; Chen Y; Zhang J
    Anal Sci; 2016; 32(12):1269-1276. PubMed ID: 27941254
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In-vitro susceptibility of the Bacteroides fragilis group to cefoperazone, ampicillin, ticarcillin and amoxycillin combined with beta-lactamase inhibitors.
    Barry AL; Jones RN; Packer RR
    J Antimicrob Chemother; 1986 Jan; 17(1):125-7. PubMed ID: 3005222
    [No Abstract]   [Full Text] [Related]  

  • 47. In-vitro pharmacodynamic simulation of clavulanic acid concentrations: effect on Staphylococcus aureus and Haemophilus influenzae beta-lactamase activity.
    Martín M; Aguilar L; Balcabao IP; Gómez-Lus ML; Dal-Ré R; Prieto J
    J Antimicrob Chemother; 1997 Feb; 39(2):290-2. PubMed ID: 9069559
    [No Abstract]   [Full Text] [Related]  

  • 48. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanic acid and sulbactam combined with ampicillin and piperacillin against beta-lactamase producing anaerobic bacteria.
    Nord CE
    J Chemother; 1989 Jul; 1(4 Suppl):273-5. PubMed ID: 16312398
    [No Abstract]   [Full Text] [Related]  

  • 49. Assays of sulbactam in the presence of ampicillin.
    Foulds G; Gans DJ; Girard D; Whall TJ
    Ther Drug Monit; 1986; 8(2):223-7. PubMed ID: 3014686
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interaction of beta-lactamase inhibitors with various beta-lactamases.
    Cullmann W
    Chemotherapy; 1990; 36(3):200-8. PubMed ID: 2159863
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-performance liquid chromatographic assay of sulbactam using pre-column reaction with 1,2,4-triazole.
    Haginaka J; Wakai J; Yasuda H; Uno T; Nakagawa T
    J Chromatogr; 1985 May; 341(1):115-22. PubMed ID: 2991310
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Overcoming resistance to beta-lactamase inhibitors: comparing sulbactam to novel inhibitors against clavulanate resistant SHV enzymes with substitutions at Ambler position 244.
    Thomson JM; Distler AM; Bonomo RA
    Biochemistry; 2007 Oct; 46(40):11361-8. PubMed ID: 17848099
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of five irreversible inhibitors on beta-lactamase from Shigella flexneri UCSF-129.
    Campos M; Alarcón MA; González H; Sánchez R
    Microbios; 1993; 76(308):171-9. PubMed ID: 8302198
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of a beta-lactamase produced by Pseudomonas paucimobilis.
    Corkill JE; Hart CA; McLennan AG; Aspinall S
    J Gen Microbiol; 1991 Jun; 137(6):1425-9. PubMed ID: 1655952
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of the beta-lactamases of Branhamella catarrhalis by clavulanic acid and other inhibitors.
    Farmer T; Reading C
    Drugs; 1986; 31 Suppl 3():70-8. PubMed ID: 3488199
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stability of beta-lactamase inhibitors and beta-lactam antibiotics in parenteral dosage forms and in body fluids and tissue homogenates: a comparative study of sulbactam, clavulanic acid, ampicillin and amoxycillin.
    Wildfeuer A; Räder K
    Int J Antimicrob Agents; 1996 Apr; 6 Suppl():S31-4. PubMed ID: 18611717
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synergy of clavulanic acid, sulbactam and tazobactam (YTR 830) with amoxycillin against fifty beta-lactamase-producing strains of Haemophilus influenzae.
    Simonet M; Moittie D; Philippon A; Descamps P; Veron M
    J Antimicrob Chemother; 1989 May; 23(5):798-800. PubMed ID: 2547748
    [No Abstract]   [Full Text] [Related]  

  • 58. Penetration of beta-lactamase inhibitors into the periplasm of gram-negative bacteria.
    Farmer TH; Degnan BA; Payne DJ
    FEMS Microbiol Lett; 1999 Jul; 176(1):11-5. PubMed ID: 10418127
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evolution of beta-lactamase inhibitors.
    Jackson D
    Pharmacotherapy; 1991; 11(2 ( Pt 2)):37S-39S. PubMed ID: 2041830
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increase in the activity of third-generation cephalosporins in combination with clavulanic acid and Sulbactam against Bacteroides fragilis.
    Martín MA; Castillo AM; Liebana J; Mesa P; Piedrola G; Gutierrez J
    Med Lab Sci; 1990 Jul; 47(3):163-7. PubMed ID: 2402195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.